Login / Signup

Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy.

Jorge Alberto Roacho-PérezElsa N Garza-TreviñoPaulina Delgado-GonzalezZuca G-BuentelloJuan Luis Delgado GallegosChristian Chapa-GonzalezMargarita Sanchez-DominguezCelia Nohemí Sánchez-DomínguezJosé Francisco Islas
Published in: Life (Basel, Switzerland) (2021)
Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which produce several side effects. This review focuses on the use of targeted nanoparticles, such as metallic nanoparticles, polymeric nanoparticles, liposomes, micelles, and carbon nanotubes as an alternative to standard treatment for pancreatic cancer. The principal objective of nanoparticles is reduction of the side effects that conventional treatments produce, mostly because of their non-specificity. Several molecular markers of pancreatic cancer cells have been studied to target nanoparticles and improve current treatment. Therefore, properly functionalized nanoparticles with specific aptamers or antibodies can be used to recognize pancreatic cancer cells. Once cancer is recognized, these nanoparticles can attack the tumor by drug delivery, gene therapy, or hyperthermia.
Keyphrases
  • drug delivery
  • cancer therapy
  • gene therapy
  • randomized controlled trial
  • stem cells
  • clinical trial
  • radiation therapy
  • mass spectrometry
  • bone marrow
  • young adults
  • replacement therapy
  • solid state